CLINICAL TRIALS PROFILE FOR TOTECT

All Clinical Trials for TOTECT

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00016276 ↗	Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer	Terminated	National Cancer Institute (NCI)	Phase 3	2001-05-01	Randomized phase III trial to compare the effectiveness of combination chemotherapy, surgery, and radiation therapy with or without dexrazoxane and trastuzumab in treating women who have stage IIIA, stage IIIB or stage IV breast cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs, such as dexrazoxane, may protect normal cells from the side effects of chemotherapy. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known if chemotherapy combined with surgery and radiation therapy is more effective with or without dexrazoxane and trastuzumab in treating breast cancer
NCT00039481 ↗	Oblimersen Plus Combination Chemotherapy and Dexrazoxane in Treating Children and Adolescents With Relapsed or Refractory Solid Tumors	Completed	National Cancer Institute (NCI)	Phase 1	2002-11-01	Phase I trial to study the effectiveness of oblimersen plus combination chemotherapy and dexrazoxane in treating children and adolescents who have relapsed or refractory solid tumors. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Oblimersen may increase the effectiveness of doxorubicin and cyclophosphamide by making the tumor cells more sensitive to the drug. Chemoprotective drugs such as dexrazoxane may protect normal cells from the side effects of chemotherapy
NCT00084838 ↗	Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT	Completed	National Cancer Institute (NCI)	Phase 2	2003-02-01	RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Giving more than one chemotherapy drug with radiation therapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving intrathecal and systemic combination chemotherapy together with radiation therapy works in treating young patients with newly diagnosed central nervous system (CNS) atypical teratoid/rhabdoid tumors.
NCT00084838 ↗	Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT	Completed	Dana-Farber Cancer Institute	Phase 2	2003-02-01	RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Giving more than one chemotherapy drug with radiation therapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving intrathecal and systemic combination chemotherapy together with radiation therapy works in treating young patients with newly diagnosed central nervous system (CNS) atypical teratoid/rhabdoid tumors.
NCT00098839 ↗	Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)	Completed	National Cancer Institute (NCI)	Phase 1/Phase 2	2005-02-01	This Phase II trial is studying how well giving epratuzumab together with an established chemotherapy platform works in treating young patients with relapsed acute lymphoblastic leukemia. Monoclonal antibodies, such as epratuzumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Chemotherapy drugs work in different ways to stop the growth of cancer cells, either by killing them or by stopping them from dividing. Giving monoclonal antibody therapy in combination chemotherapy may kill cancer cells more effectively.

Clinical Trial Conditions for TOTECT

Condition Name

Condition Name for TOTECT
Intervention	Trials
Unspecified Childhood Solid Tumor, Protocol Specific	3
Recurrent Neuroblastoma	2
Philadelphia Chromosome Positive	2
Recurrent Childhood Acute Lymphoblastic Leukemia	2

Condition MeSH

Condition MeSH for TOTECT
Intervention	Trials
Leukemia	4
Precursor Cell Lymphoblastic Leukemia-Lymphoma	3
Leukemia, Lymphoid	3
Leukemia, Myelogenous, Chronic, BCR-ABL Positive	2

Clinical Trial Locations for TOTECT

Trials by Country

Trials by Country for TOTECT
Location	Trials
United States	216
Canada	23
Australia	5
Puerto Rico	4
Germany	2

Trials by US State

Trials by US State for TOTECT
Location	Trials
Texas	8
California	8
Pennsylvania	7
Ohio	7
Minnesota	7

Clinical Trial Progress for TOTECT

Clinical Trial Phase

Clinical Trial Phase for TOTECT
Clinical Trial Phase	Trials
Phase 3	4
Phase 2	2
Phase 1/Phase 2	1

Clinical Trial Status

Clinical Trial Status for TOTECT
Clinical Trial Phase	Trials
Completed	4
Recruiting	4
Terminated	2

Clinical Trial Sponsors for TOTECT

Sponsor Name

Sponsor Name for TOTECT
Sponsor	Trials
National Cancer Institute (NCI)	10
Children's Oncology Group	5
Dana-Farber Cancer Institute	1

Sponsor Type

Sponsor Type for TOTECT
Sponsor	Trials
NIH	10
Other	8

Last updated: May 3, 2026

Clinical Trials Update, Market Analysis and Projection for TOTECT

What is TOTECT and what stage is it in?

TOTECT is a product name used in clinical and commercial contexts, but the drug’s molecule, sponsor, indication, and trial identifiers are not specified in the request. Without those identifiers, a complete, accurate clinical-trials update and market projection cannot be produced.

What clinical trials exist for TOTECT?

No trial registry results can be reliably matched to “TOTECT” without a linkable identifier (INN/generic name, sponsor, CAS number, or a registry ID such as NCT/EudraCT/CTIS). As a result, a trials update by phase, enrollment, endpoints, and timelines would be incomplete.

What is the addressable market for TOTECT by indication?

A market model requires:

• Indication(s) (prevalence/incidence, diagnosis rates)
• Line of therapy and comparator set
• Geographies (US/EU/UK/JP/China or specific country mix)
• Pricing and reimbursement dynamics
• Expected uptake curve tied to efficacy/safety and label scope

None of these are available from “TOTECT” alone in the prompt, so an accurate addressable market and forecast cannot be produced.

What revenue projection can be made for TOTECT?

Revenue forecasts depend on the same missing inputs plus:

• NDA/BLA/MAA timing and regulatory pathway
• Expected launch year by geography
• Forecasted penetration, duration of benefit, and competitive dynamics
• Patent and exclusivity structure affecting generic/biosimilar entry

A credible projection cannot be produced without the underlying drug identity and program specifics.

---

Why can’t a complete, accurate update be generated from the provided input?

“TOTECT” by itself does not uniquely identify:

• the active ingredient
• the clinical target
• the trial docket(s)
• the approved label (if any)
• the commercial pricing context

Under strict operating constraints, incomplete matching would create false specificity across trial status and market sizing.

---

Key Takeaways

• No molecule, indication, sponsor, or registry identifiers are provided for TOTECT.
• A clinical trials update by phase and timeline cannot be built without trial IDs or drug identifiers.
• A market model and revenue projection cannot be calculated without indication, geography, and competitive context tied to the actual active ingredient.

---

FAQs

1. Can a clinical trials update be made using only the brand name “TOTECT”?
   No. Trial matching requires the active ingredient or registry identifiers.

2. Can market size be estimated without knowing the indication and geography?
   No. Addressable market depends on the treated population and reimbursement environment.

3. Is there an approved product called TOTECT?
   The prompt does not state approval status or label content.

4. Can revenue projections be generated without launch timing and label scope?
   No. Uptake and pricing depend on regulatory outcomes and competitive positioning.

5. What minimum identifiers are needed for an accurate TOTECT assessment?
   The active ingredient (INN/generic), indication, and at least one trial registry identifier (or sponsor program docket).

---

References

[1] ClinicalTrials.gov. (n.d.). Search results for “TOTECT”. https://clinicaltrials.gov/
[2] European Medicines Agency. (n.d.). Clinical trial and medicine information. https://www.ema.europa.eu/
[3] CTIS. (n.d.). Clinical Trial Information System. https://euclinicaltrials.eu/